Leah Kuntz

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The latest in mood disorder news, all in one place.

Eisai and Biogen announced they have initiated a rolling submission for subcutaneous Leqembi for Alzheimer disease.

H. Steven Moffic, MD, received the Abraham Halpern Humanitarian Award at the 2024 American Psychiatric Association Annual Meeting. Here’s what he spoke about during his acceptance.

TEV-‘749, an investigational once-monthly subcutaneous long-acting injection of the 2nd generation antipsychotic olanzapine, sees positive phase 3 results.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.

Petros Levounis, MD, MA, talks addiction, buprenorphine, his year as president of the APA, and more at the 2024 Annual Meeting.

This 2024 APA Annual Meeting poster investigated the relationship between antiobesity agents like semaglutide and depression.

This 2024 APA Annual Meeting poster covered a literature review on the relationship between stimulant use and failure to thrive in pediatric patients with ADHD.

Use this protocol, presented at the 2024 APA Annual Meeting, in patients with cannabis use disorder to bolster likelihood of cannabis cessation or reduction in use.

This interactive installation begs the question, “What is the truth of life with schizophrenia?”

What are the cultural psychiatry perspectives on personality disorders? Don't miss this APA session!

The addition of 30 mg of evenamide to patients’ current antipsychotic medication was associated with a highly statistically significant reduction in the PANSS Total Score.

Check out new positive topline data from the SAVITRI study assessing the efficacy and safety of NBI-1065845 in adults with major depressive disorder.

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints of a new phase 3 study.

Are you ready to discuss the Black youth crisis and the need for dynamic conversations?

Learn more about the latest data on KarXT, which is posed to be the first new pharmacological treatment for schizophrenia.

Rejoyn was recently cleared by the FDA, making it the first prescription digital therapeutic for major depressive disorder.

The suicide rate in the United States recently reached its highest peak since 1941.

Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!

New phase 2 study initiated to determine the potential of ALTO-203 as an antidepressant in patients with major depressive disorder and anhedonia.

The FDA has cleared the first prescription digital therapeutic for major depressive disorder, Rejoyn.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

Join us in congratulating Dr Tampi on his recent win of the American Association for Geriatric Psychiatry’s Diversity Award!

A new study found that when glucose is either very high or low in patients with type 1 diabetes, cognition is slower; however, slightly above average glucose led to peak cognitive performance.

Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.

New research on transcranial direct current stimulation effectiveness in treating major depressive disorder.

Alzheimer disease treatment donanemab will be delayed as the FDA plans to convene a committee meeting to evaluate the phase 3 Trailblazer-Alz 2 trial.